On March 19 Taysha Gene Therapies provided clinal updates on its gene therapy clinical trials for Rett syndrome. Here is a summary of the updates:
- Data from a 35-week assessment of the first adult patient in the REVEAL study showed that the TSHA-102 gene therapy low dose was well tolerated with sustained improvement across various efficacy measures.
- Data from a 19-week assessment of the second adult patient, also given a low dose, showed that the gene therapy was well-tolerated and indicated improvement in various efficacy measures.
- An Independent Data Monitoring Committee gave approval to proceed to the higher dose in the adolescent and adult study and to dose a second pediatric patient at the lower dose.
- Initial data from the first cohort (low dose) of the pediatric trial is expected in mid-2024. And initial data from the second cohort (high dose) in both pediatric and adolescent/adult trials is expected in the second half of the year.
The Principal Investigator of the REVEAL trial taking place at CHU Sainte-Justine Research Center in Montreal Canada stated: “Both adult patients treated with TSHA-102 showed sustained and new improvements across key areas of disease impacting activities of daily living, including multiple aspects of autonomic function, social communication, motor skills, and experienced stabilized or significantly reduced seizures.”
Please explore the links below for additional details.